Livongo Reports Fourth Quarter and Full Year Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall St awaits Nvidia's AI verdict after hot inflation data
- Oil rises as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Citi sees an opportunity in Oracle after ’one of the most extreme’ stock drawdowns
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Livongo Health (LVGO) Tops Q4 EPS by 7c, Revenues Beat; Offers Q1 & FY20 Revenue Guidance Above Consensus
March 2, 2020 4:18 PM ESTLivongo Health (NASDAQ: LVGO) reported Q4 EPS of $0.02, $0.07 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $50.2 million versus the consensus estimate of $49.27 million.
Fourth Quarter 2019 Highlights:
ASC 606:
Revenue: Total revenue for the quarter was $50.4 million, up 137% year-over-year. Gross Margin: GAAP gross margin of 78.3% and non-GAAP gross margin of 79.2%, which reflects continued scaling in the delivery of our offerings and includes an adjustment related to capitalization of device costs for certain solutions. Net Loss: GAAP net loss of $6.0 million, and net loss per share... More